Compare Novartis AG (NVS) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.72. The key difference: Novartis AG pays a 3.17% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Novartis AG is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| NVS | YINN | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $56.62 |
52-Week Low | $113.50 | $21.45 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $28.89, up 7.84% with strong bullish technical signals from moving averages and ADX indicators. The leveraged ETF structure amplifies exposure to Chinese equities, which face mixed sentiment amid US-China tech tensions but show resilience through AI and semiconductor sector strength. Recent news highlights China's $295 billion AI infrastructure plan and export growth exceeding expectations.
Outlook remains cautiously optimistic given China's tech sector momentum and infrastructure investments, though leveraged ETF risks and geopolitical tensions pose significant volatility. The fund's 3x daily leverage requires careful risk management amid ongoing regulatory scrutiny and market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
